1. Home
  2. RVMDW vs MRK Comparison

RVMDW vs MRK Comparison

Compare RVMDW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • MRK
  • Stock Information
  • Founded
  • RVMDW 2014
  • MRK 2000
  • Country
  • RVMDW United States
  • MRK United States
  • Employees
  • RVMDW N/A
  • MRK N/A
  • Industry
  • RVMDW
  • MRK Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVMDW
  • MRK Health Care
  • Exchange
  • RVMDW Nasdaq
  • MRK Nasdaq
  • Market Cap
  • RVMDW N/A
  • MRK N/A
  • IPO Year
  • RVMDW N/A
  • MRK N/A
  • Fundamental
  • Price
  • RVMDW $0.10
  • MRK $83.01
  • Analyst Decision
  • RVMDW
  • MRK Buy
  • Analyst Count
  • RVMDW 0
  • MRK 15
  • Target Price
  • RVMDW N/A
  • MRK $121.79
  • AVG Volume (30 Days)
  • RVMDW 15.6K
  • MRK 17.8M
  • Earning Date
  • RVMDW 02-26-2025
  • MRK 02-04-2025
  • Dividend Yield
  • RVMDW N/A
  • MRK 3.90%
  • EPS Growth
  • RVMDW N/A
  • MRK 4711.66
  • EPS
  • RVMDW N/A
  • MRK 6.74
  • Revenue
  • RVMDW $742,000.00
  • MRK $64,168,000,000.00
  • Revenue This Year
  • RVMDW N/A
  • MRK $5.72
  • Revenue Next Year
  • RVMDW N/A
  • MRK $5.97
  • P/E Ratio
  • RVMDW N/A
  • MRK $12.32
  • Revenue Growth
  • RVMDW N/A
  • MRK 6.74
  • 52 Week Low
  • RVMDW $0.10
  • MRK $82.09
  • 52 Week High
  • RVMDW $0.12
  • MRK $134.63
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • MRK 21.34
  • Support Level
  • RVMDW N/A
  • MRK $87.33
  • Resistance Level
  • RVMDW N/A
  • MRK $100.15
  • Average True Range (ATR)
  • RVMDW 0.00
  • MRK 1.91
  • MACD
  • RVMDW 0.00
  • MRK -1.10
  • Stochastic Oscillator
  • RVMDW 0.00
  • MRK 5.07

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: